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This Book of the Seton Hall Law Review presents the contribu-
tions to Follow-On Biologics: Implementation Challenges and Opportunities, 
a one-day roundtable event hosted by Seton Hall University School of 
Law in the fall of 2010.
1
  The roundtable fostered an international di-
alogue regarding the future of follow-on biologics in the United 
States resulting from the Patient Protection and Affordable Care Act 
of March 2010. 
I. THE BIOLOGIC PRICE COMPETITION AND INNOVATION ACT OF 2010 
The March 23, 2010, enactment of the Patient Protection and 
Affordable Care Act (PPACA)
2
 and the companion Health Care and 
Education Affordability Reconciliation Act of 2010
3
 ushered in land-
mark reform of the American health care system.  Along with sweep-
ing overhauls of the health care system generally, PPACA also pro-
vides a new regulatory challenge for the Food and Drug 
Administration (FDA).  A subtitle within PPACA, the Biologics Price 
Competition and Innovation Act (BPCIA),
4
 bestows upon FDA broad 
authority to implement an abbreviated approval route to market for 
 
 ∗ Associate Professor of Law, Seton Hall University School of Law.  J.D., Chicago-
Kent College of Law; B.S., University of Michigan.  
 1 The roundtable was co-sponsored by the Gibbons Institute for Law, Science & 
Technology and the Center for Health & Pharmaceutical Law & Policy at Seton Hall 
University School of Law.  The author would like to thank all roundtable presenters 
and participants for contributing to the event and to particularly thank Donna M. 
Gitter and Henry Grabowski (and co-authors) for developing full-length Articles for 
this Book of the Seton Hall Law Review. 
 2 Pub. L. No. 111-148, 124 Stat. 119 (2010) (codified in scattered sections of 21 
U.S.C, 35 U.S.C., and 42 U.S.C.). 
 3 Pub. L. No. 111-152, 124 Stat. 1029 (2010).  
 4 Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §§ 7001–03, 
124 Stat. 119, 804–21 (2010) [hereinafter BPCIA]. 
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biological products (also known as biologics) that are “biosimilar” to 
an existing marketed product.
5
 
This brief introduction will provide a basic comparison of bi-
ologics and conventional pharmaceutical drugs that will prove central 
to the FDA’s development of this follow-on biologic pathway as well as 
specifically examine the content and scope of the BPCIA provisions 
and identify future challenges for the FDA.  It will conclude by hig-
hlighting details of presentations during the roundtable held at the 
Seton Hall University School of Law and introduce the two resulting 
articles contained within this Book of the Seton Hall Law Review.
6
 
II. COMPARING BIOLOGICS AND PHARMACEUTICAL DRUGS 
Biologics are medical products derived from living sources (an-
imals, humans, and microorganisms) and include viruses, therapeutic 
serums, toxins and antitoxins, vaccines, blood and blood products, 
and cells, tissues and gene therapy products.
7
  As described by the 
FDA, biological products are divided into a number of categories: al-
lergenics, including allergen patch tests and allergenic extracts; 
blood and blood products, including blood, blood components, 
blood bank devices, and blood donor screening tests; cellular and 
gene therapy products, including gene-based and cell-based treat-
ments; tissue and tissue products, including bone, skin, corneas, li-
gaments, tendons, and stem cells; vaccines; and xenotransplantation 




 5 42 U.S.C. § 262(i)(1) (Supp. IV 2010).  The new follow-on biologics provisions 
create statutory mechanisms to provide for approval of a biological product that is 
“biosimilar” and/or “interchangeable” with a biologic reference product already on 
the market.  § 262(i)(3).  This status is to be based on whether a follow-on product is 
“highly similar” to the reference product. § 262(i)(2).   
 6 Henry Grabowski, Genia Long & Richard Mortimer, Implementation of the Biosi-
milar Pathway: Economic and Policy Issues, 41 SETON HALL L. REV. 511 (2011); Donna M. 
Gitter, Informed by the European Union Experience: What the United States Can Anticipate 
and Learn from the European Union’s Regulatory Approach to Biosimilars, 41 SETON HALL L. 
REV. 559 (2011). 
 7 § 262(i).  A biological product is defined as 
a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood 
component or derivative, allergenic product, protein (except any 
chemically synthesized polypeptide) or analogous product, or arsphe-
namine or derivative of arsphenamine (or any other trivalent organic 
arsenic compound), applicable to the prevention, treatment, or cure of 
a disease or condition of human beings. 
Id. 
 8 Transfer of Therapeutic Biological Products to the Center for Drug Evaluation and Re-
search, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/CombinationProducts/ 
JurisdictionalInformation/ucm136265.htm (last visited Jan. 30, 2011). 
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Biologics differ from traditional pharmaceutical drugs in a 
number of ways—aside from their origination from living rather than 
chemically synthesized sources, they are also more complex macro-
molecular entities, they are typically manufactured using more so-
phisticated techniques, and they are more susceptible to variations in 
final product given manufacturing and storage conditions.  Biologics 
consist of proteins whose structure is determined by four organiza-
tional levels: their amino acid sequence, their spatial configuration, 
any three-dimensional folding that occurs, and their interactions.
9
  
The final product is largely dependent on manufacturing process 
used and there can be variation in biological activity due to media, 
temperature, and other interactions.
10
  Approval is achieved through 
either the Center for Biologics Evaluation and Research or the Cen-
ter for Drug Evaluation and Research (CDER) depending on product 
type.
11




Conventional pharmaceutical drugs, on the other hand, are 
small molecules that are chemically synthesized and relatively simple 
to characterize compared to biologics.
13
  They are approved through 
the New Drug Application (NDA) process overseen by CDER after 
proving safety and efficacy and fulfilling all other substantive re-
quirements of the Food, Drug and Cosmetic Act (FDCA).
14
  Two ab-
breviated routes to market exist for new drugs within the FDCA—one 
of which is the generic route to market, or the Abbreviated New Drug 
Application (ANDA).
15
  In 1997, the Food and Drug Administration 
 
 9 See JUDITH A. JOHNSON, CONG. RESEARCH SERV., FDA REGULATION OF FOLLOW-ON 
BIOLOGICS 10 (Apr. 26, 2010), available at http://www.primaryimmune.org/ 
advocacy_center/pdfs/health_care_reform/Biosimilars_Congressional_Research_ 
Service_Report.pdf. 
 10 Id. 
 11 About the Center for Drug Evaluation and Research, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/AboutFDA/CentersOffices/CDER/default.htm (last visited Jan. 
30, 2011); Center for Biologics Evaluation and Research (CBER) Responsibilities Questions 
and Answers, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/ 
CentersOffices/CBER/ucm133072.htm (last visited Jan. 30, 2011). 
 12 42 U.S.C. § 262(a) (Supp. IV 2010).   
 13 See JOHNSON, supra note 9, at Summ. 
 14 See Food, Drug and Cosmetic Act (FDCA), Pub. L. 75-717, § 505(b), 52 Stat. 
1040 (1938) (codified at 21 U.S.C. § 355(b) (Supp. IV 2010)); New Drug Application 
(NDA), U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/ 
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approval 
Applications/NewDrugApplicationNDA/default.htm (last visited Jan. 30, 2011). 
 15 These two routes are the ANDA and the § 505(b)(2) process set out in FDCA § 
505(j) and § 505(b)(2).  21 U.S.C. §§ 355(j), 355(b)(2).  Over the counter (OTC) 
drugs adhering to an OTC Monograph can enter the market without the new drug 
PARADISE.DOCX (DO NOT DELETE) 4/19/2011  7:13 AM 
504 SETON HALL LAW REVIEW [Vol. 41:501 
Modernization Act amended both the PHSA and FDCA to create un-
iformity in the NDA and Biologics License Application (BLA) ap-
proval processes, yet they remain under separate statutory authority.
16
  
A BLA is issued by the FDA after finding that the product is safe, 
pure, and potent and that the manufacturing facility assures this;
17
 it 
thus incorporates classic FDCA provisions and structures of investiga-
tional new drug applications (INDs) for initiation and progress of 
clinical trials and similar measures of safety and efficacy of NDAs, in-
cluding good manufacturing practices and post-market mechanisms. 
Despite the parallels in the NDA approval process for pharma-
ceutical drugs
18
 and the BLA approval process for biologics,
19
 the sta-
tutory and regulatory mechanisms permitting generic approval, mar-
ket exclusivity and patent exclusivity provisions did not previously 
exist for biologics due to the bifurcated statutory authority—the drug 
approval process residing in the FDCA and the biologics approval 
pathway residing in the PHSA.  Previous implementation of the 
ANDA (generic drug) process amended the FDCA, not the PHSA, 
and thus the abbreviated approval pathway and accompanying patent 
and exclusivity provisions of the Hatch-Waxman Act of 1984 did not 
cover biologics.
20
  The core requirement for generic drug sponsors 
utilizing the ANDA route is to show “bioequivalence” to the pioneer 
drug based on comparison studies rather than extensive clinical trials 
 
process, as they are regarded as “generally recognized as safe and effective.”  21 CFR 
330.1 (2010). 
 16 See Food and Drug Administration Modernization Act (FDAMA) of 1997, Pub. 
L. 105-115, § 112, 111 Stat. 2296. 
 17 42 U.S.C. § 262(a)(2)(C)(i) (Supp. IV 2010).   
 18 A drug is defined as: 
(A) articles recognized in the official U.S. Pharmacopeia, . . . and (b) 
articles intended for use in the diagnosis, cure, mitigation, treatment, 
or prevention of disease in man or other animals; and (c) articles (oth-
er than food) intended to affect the structure or any function of the 
body of man or other animals; and (d) articles intended for use as a 
component . . . .   
FDCA § 201(g)(1).  A new drug is defined as: 
(1) Any drug (except a new animal drug or an animal feed bearing or 
containing a new animal drug) the composition of which is such that 
the drug is not generally recognized, among experts qualified by scien-
tific training and experience to evaluate the safety and effectiveness of 
drugs, as safe and effective for use under the conditions prescribed, 
recommended, or suggested in the labeling . . . . 
§ 201(p)(1).  
 19 42 U.S.C. § 262 (Supp. IV 2010).   
 20 See FDCA, Pub. L. 75-717, § 505(j).  This legislation implemented the generic 
drug approval process and related exclusivity incentives.  Id. 
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showing safety and efficacy required in the NDA process.
21
  The 
ANDA process allows a generic drug sponsor to enter the market sub-
ject to certain patent certifications that directly assert that a pioneer 
drug is invalid or unenforceable.
22
  The first successful generic spon-
sor to assert such a certification in their ANDA application receives 




The lack of an abbreviated approval process for biologics prior 
to the BPCIA has assured pioneer biologics a long term of patent 
protection and financial profit.  The Federal Trade Commission re-
ports that in 2007 alone Americans spent $40.3 billion on biologics 
(out of a total $286.5 billion for prescription drugs), with an individ-
ual cost of common treatments for rheumatoid arthritis and breast 
cancer costing patients $20,000 and $48,000 per year, respectively.
24
  
A New York Times Op-Ed offers that some biologics exceed $200,000 
per year.
25
  That same article reports that biologics, on average, cost 
twenty-two times that of ordinary drugs and that the six top-selling 
biologics make up 43% of the Medicare Part B drug budget.
26
  Given 
that the first generic pharmaceutical drug to enter the market gener-
ally offers a price discount 25% lower than pioneer (rising to 80% 
price discount with multiple generics on the market),
27
 the hope is 
that a follow-on biologics pathway will provide similar savings. 
III. CONCEPTS OF “BIOSIMILARITY” 
Driven largely by the decades-long debate on the rising costs of 
biologics, the BPCIA is aimed at curbing these costs both to consum-
ers and federal reimbursement schemes by creating a generic-like 
route to market for biosimilar biological products.
28
  The BPCIA 
 
 21 § 505(j)(2)(A)(iv).  
 22 § 505(j)(2)(A)(i)–(viii). 
 23 § 505(j)(2)(A)(iii)–(iv). 
 24 FED. TRADE COMM’N, EMERGING HEALTH CARE ISSUES: FOLLOW-ON BIOLOGIC 
DRUG COMPETITION, at i (2009) [hereinafter FTC REPORT], available at 
http://www.ftc.gov/os/2009/06/P083901biologicsreport.pdf.  The report provides 
that patients pay $20,000/year for Remicade (for treatment of Rheumatoid arthritis) 
and $48,000/year for Herceptin (for treatment of breast cancer).  Id.  
 25 Anthony D. So & Samuel L. Katz, Op-Ed, Biologics Boondoggle, N.Y. TIMES, Mar. 
8, 2010, at A23.  This article reports that patients pay $200,000/year for Cerezyme 
(for treatment of Gaucher disease).  Id. 
 26 Id. 
 27 FTC REPORT, supra note 24, at 12.  
 28 See Implementation of the Biologics Price Competition and Innovation Act of 2009, U.S. 
FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/GuidanceCompliance 
RegulatoryInformation/ucm215089.htm (last visited Feb. 2, 2011).  Some argue fol-
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creates an approval pathway for submission of a BLA for a “biosimi-
lar” and/or “interchangeable” biologic.
29
  Biosimilarity is defined 
within the legislation to mean that “the biological product is highly 
similar to the reference product notwithstanding minor differences 
in clinically inactive components,” and “there are no clinically mea-
ningful differences between the biological product and the reference 
product in terms of . . . safety, purity, and potency.”
30
  Interchangea-
bility is defined to mean that the requirements for “biosimilarity” are 
fulfilled and the biological product “may be substituted for the refer-
ence product without the intervention of the health care provider 
who prescribed the reference product.”
31
 
While the specific details of the new process have been left to 
the FDA, Congress provided some general guidance.  The biosimilari-
ty BLA application content must include analytical studies, animal 
studies, and a clinical study or studies with the following require-
ments: they must have the same mechanism(s) of action for condi-
tion(s) of use that “have been previously approved for the reference 
product”: they must have the same route of administration, dosage 
form, and strength; and the facility must assure the development of a 
safe, pure, and potent product.
32
  However, the legislation also specif-
ically gives FDA discretion to decide requirements on a case-by-case 
basis.
33
  For a finding of interchangeability, the BLA application con-
tent must be biosimilar plus include a showing of the expectation to 
provide the same clinical result as the reference product in any given 
patient
34
 and a showing that where “administered more than once to 
an individual, the risk in terms of safety of diminished efficacy of al-
ternating or switching between use of the biological product and the 
 
low-on biologics should not be referred to as “generic” biologics due to the differ-
ences in characteristics described above.  See Susan Aldridge, Why Biosimilars Are Not 
True Generics, PHARMACEUTICAL TECHNOLOGY EUROPE, June 1, 2007, 
http://pharmtech.findpharma.com/pharmtech/Biopharmaceuticals/Why-
biosimilars-are-not-true-generics/ArticleStandard/Article/detail/435320.  The 
phrase “highly similar” as laid out in the BPCIA is not the same as “bioequivalence” 
as utilized in generic determinations.  Federal regulations define bioequivalence as 
“the absence of a significant difference in the rate and extent to which the active in-
gredient or active moiety in pharmaceutical equivalents or pharmaceutical alterna-
tives becomes available at the site of drug action when administered at the same mo-
lar dose under similar conditions in an appropriately designed study.”  21 C.F.R. § 
320.1(e) (2010). 
 29 42 U.S.C. § 262(i)(1) (Supp. IV 2010).  
 30 § 262(i)(2).   
 31 § 262(i)(3).   
 32 § 262(k)(2)(A)(i). 
 33 § 262(k)(2)(A)(ii). 
 34 § 262(k)(3).  
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reference product is not greater than the risk of using the reference 
product without such alternation or switch.”
35
 
The BPCIA sets out to accomplish the development of the fol-
low-on biologic provisions through several key mechanisms.  First, the 
Secretary of the Department of Health and Human Services, partner-
ing with the Commissioner of the FDA, is authorized to issue “guid-
ance” regarding standards and criteria and implement approval 
processes utilizing public comment.
36
  The BPCIA also creates a 
process for the resolution of patent disputes, including disclosure re-
quirements for biosimilar applicants to the pioneer biologic and an 
ensuing back and forth system of patent status and litigation assess-
ment.
37
  There are a number of incentives to encourage follow-on de-
velopment, including a twelve-year period of market exclusivity for 
pioneer biologics,
38
 a one-year period of exclusivity for the first prod-
uct deemed “interchangeable” to a pioneer biologic,
39
 and an addi-
tional six months of exclusivity for pediatric studies.
40
  However, the 
exact type of exclusivity available under the BPCIA is currently open 
for debate.  In public notifications and requests for comment, the 
FDA has interpreted the language of the BPCIA to provide for 12 
years of market exclusivity, while some members of Congress and in-
dustry argue that it provides either for 12 years of data exclusivity or 
four years of data exclusivity followed by eight years of market exclu-
sivity.41  Specifically, the statute provides that applications “may not be 
submitted to the Secretary until the date that is four years after the 
date on which the reference product was first licensed” and that ap-
proval “may not be made effective . . . until the date that is 12 years 
after the date on which the reference product was first licensed.”42 
Aside from deciphering the expansive legislative language con-
tained within the BPCIA, core challenges for the FDA will be deter-
mining appropriate scientific and technical measures for comparison 
between the pioneer biologic and the “biosimilar” product, selecting 
how to implement regulatory mechanisms and procedures (either 
 
 35 42 U.S.C. § 262(k)(4)(A)–(B) (Supp. IV 2010). 
 36 § 262(k)(8). 
 37 § 262(l). 
 38 § 262(k)(7)(A). 
 39 § 262(k)(6)(A). 
 40 § 262(m)(2)(A). 
 41 Alicia Mundy, Firms Push for Biotech Generics, WALL ST. J., Jan. 26, 2011, 
http://online.wsj.com/article/SB10001424052748704013604576104413760150024.h
tml; Derrick Gingery, Biosimilars Exclusivity Tug-of-War Brewing in the Mail; Can a Letter 
Add Eight Years to Reviews?, PINK SHEET, Jan. 31, 2011, at 9. 
 42 PHSA, §351(k)(7)(A)–(C)(2010)(codified at 42 U.S.C. §262(k)(7)(A)–(C)).  
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through rulemaking, guidance documents, or on a case-by-case ba-
sis), and navigating its role in the novel patent and exclusivity provi-
sions. 
IV. SETON HALL UNIVERSITY SCHOOL OF LAW ROUNDTABLE 
On October 29, 2010, Seton Hall University School of Law 
hosted a roundtable event addressing the BPCIA provisions and the 
future of the new biosimiliar pathway, entitled “Follow-On Biologics: 
Implementation Challenges and Opportunities.”  Roundtable partic-
ipants represented a range of perspectives and professional discip-
lines spanning law, science, health, economics, and public policy.  
The event examined the current legal status of follow-on biologics, 
specifically exploring the legislative provisions; scientific and regula-
tory distinctions between the established generic drug approval 
processes and the new yet to be determined approval process for fol-
low-on biologics, focusing on differences between traditional phar-
maceutical drugs and biologics based on size, characteristics, com-
plexity, manufacturing processes, reproducibility, and concepts of 
similarity and interchangeability; comparisons of the BPCIA with in-
ternational oversight of follow-on biologics in the European Union; 
market and patent exclusivity concerns, particularly Hatch-Waxman 
issues; and overarching concerns for industry and consumers. 
National and international experts kicked off the event with ple-
nary presentations on various aspects of the legislation that promise 
to pose challenges to the existing oversight regime for biological 
products in the United States.  In order to frame the discussion, Dr. 
Falk Ehmann, M.D., Ph.D., M.Sc. (Scientific Secretariat of the Euro-
pean Medicines Agency’s Biosimilar Working Party; Safety & Efficacy 
of Medicines Sector, Human Medicines Development and Evaluation 
Unit), presented on “Biosimilars in the European Union: From Legis-
lation to Future Challenges—Experiences and Perspectives.”  He 
highlighted the core implementation mechanisms, current scientific 
questions, and future goals for the European Union, which has had a 
follow-on biologic pathway since 2005.  Suzanne Drennon Munck, 
J.D. (Counsel for Intellectual Property for the Federal Trade Com-
mission), spoke on the topic of “Follow-On Biologics: A Federal 
Trade Commission Perspective,” providing background on FTC activ-
ity and its position on the follow-on pathway to market, focusing on 
her own perspective of barriers to competition introduced with the 
patent resolution process and patent exclusivity periods in the new 
legislation.  Dr. Henry Grabowski, Ph.D. (Professor of Economics and 
Director of the Program in Pharmaceuticals and Health Economics at 
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Duke University), discussed “Implementation of the Biosimilar Path-
way: Economic and Policy Issues,” offering an economic analysis of 
the effects of the new follow-on provisions, specifically examining 
health care cost savings and innovation incentive aspects of the 
BPCIA’s data and patent exclusivity provisions. 
The afternoon consisted of a traditional roundtable format, al-
lotting time to seven expert panelists to present among colleagues 
and actively discuss particular aspects of the follow-on provisions with 
both the morning plenary presenters and the audience.  Jill Deal, J.D. 
(Partner at Venable LLP), forecasted FDA moves using generic 
Enoxapirin (Lovenox®) as a case study.
43
  Phil Katz, J.D. (Partner and 
Practice Area Leader of Pharmaceuticals & Biotechnology at Hogan 
Lovells), examined current FDA activity and future concerns con-
fronted by the FDA in implementing the new legislation.
44
  Dr. Wil-
liam M. Egan, Ph.D. (Vice President of PharmaNet Consulting), dis-
cussed a variety of technical and scientific questions regarding “highly 
similar” measures and “interchangeability” including adequacy of in-
ternational naming standards.
45
  Reza Green, Ph.D., J.D. (Chief Intel-
lectual Property Counsel of Novo Nordisk), examined the back-and-
forth patent disclosure mechanisms in the BPCIA, discussing difficul-
ties for both the pioneer biologic and the follow-on biologic sponsor 
in the areas of confidentiality, pre-litigation admissions, and pre-
existing licensing agreements.
46
  Chris Holman, Ph.D., J.D. (Associate 
Professor of Law at the University of Missouri-Kansas City School of 
Law), assessed the landscape of biologic patents, comparing and con-
trasting them with patents for conventional pharmaceutical drugs.
47
  
Nathan Cortez, J.D. (Assistant Professor of Law at Southern Method-
ist University Dedman School of Law), mapped the international le-
gal authority for post-marketing and pharmacovigilence for follow-on 
biologics in the European Union, Japan, and Canada.
48
  Donna Git-
ter, J.D. (Associate Professor of Law at Baruch College, The City Uni-
 
 43 The presentation was entitled “Where is FDA Likely to Go: Enoxapirin Sodium 
(Lovenox®) as a Possible Case Study.” 
 44 The presentation was entitled “Open Issues Confronted by FDA.” 
 45 The presentation was entitled “Biosimilars, Interchangeable Biosimilars, and 
the U.S. Legislation.” 
 46 The presentation was entitled “The Patent Dance: Follow-On Biologics Patent 
Disclosure Process.” 
 47 The presentation was entitled “The Role of Patents in Maintaining Market Ex-
clusivity for Biologics.” 
 48 The presentation was entitled “Charting the Global Trend towards Biosimi-
lars.” 
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versity of New York), identified lessons for the United States gleaned 
from the European Union experience.
49
 
The following two full-length Articles result from the roundtable 
experience: Henry Grabowski, Genia Long, and Richard Mortimer, 
“Implementation of the Biosimilar Pathway: Economic and Policy Is-
sues,”
50
 and Donna M. Gitter, “Informed by the European Union Ex-
perience: What the United States Can Anticipate and Learn from the 






 49 The presentation was entitled “Informed by the European Union Experience: 
What the United States Can Anticipate and Learn from the European Union’s Regu-
latory Approach to Biosimilars.” 
 50 See Grabowski et al., supra note 6. 
 51 See Gitter, supra note 6. 
